Cargando…
Checkpoint inhibitor use in two heart transplant patients with metastatic melanoma and review of high-risk populations
Due to the unique side-effect profile of immune checkpoint inhibitors (ICIs), groups of patients deemed to be at high risk of complications were excluded from trials that proved the efficacy and safety of these agents in patients with various malignancies. Among these excluded patients were those wi...
Autores principales: | Grant, Michael J, DeVito, Nicholas, Salama, April K S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Future Medicine Ltd
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240846/ https://www.ncbi.nlm.nih.gov/pubmed/30459942 http://dx.doi.org/10.2217/mmt-2018-0004 |
Ejemplares similares
-
Checkpoint Inhibitors in Melanoma Patients with Underlying Autoimmune Disease
por: Dietz, Hilary, et al.
Publicado: (2021) -
Evolving Pharmacotherapies for the Treatment of Metastatic Melanoma
por: Salama, April K.S.
Publicado: (2013) -
Identification of a Germline Pyrin Variant in a Metastatic Melanoma Patient With Multiple Spontaneous Regressions and Immune-related Adverse Events
por: Oswalt, Cameron J., et al.
Publicado: (2022) -
Survival after checkpoint inhibitors for metastatic acral, mucosal and uveal melanoma
por: Klemen, Nicholas D., et al.
Publicado: (2020) -
First-line treatment of metastatic melanoma: role of nivolumab
por: Force, Jeremy, et al.
Publicado: (2017)